Description

CJC-1295 No DAC 5mg + Ipamorelin 5mg: Product & Research Information

Product Overview

CJC-1295 No DAC 5mg + Ipamorelin 5mg is a two-peptide formulation presented for research-oriented reference. The listed composition specifies 5 mg of CJC-1295 No DAC and 5 mg of Ipamorelin, for a stated total peptide content of 10 mg per vial. These labeled quantities do not independently verify the product’s identity, purity, or quality.

The two peptides are associated with different biological signaling pathways investigated in growth hormone research. CJC-1295 No DAC is described as a growth hormone-releasing hormone (GHRH)-related peptide, while Ipamorelin is studied for its interaction with the ghrelin receptor, also known as GHS-R1a.

Although the compounds have attracted scientific interest, their presence in the same formulation does not establish clinical synergy, predictable outcomes, or safety and effectiveness in humans.

Understanding CJC-1295 No DAC

CJC-1295 No DAC is a name commonly used for a modified GHRH-related peptide without the Drug Affinity Complex modification associated with longer-acting CJC-1295 formulations. Commercial naming is not always consistent, so the precise molecular identity and chemical form should be confirmed through reliable product documentation.

GHRH signaling is involved in the regulation of growth hormone release by the pituitary gland. However, a plausible biological mechanism is not the same as evidence that a product produces a particular health, performance, or body-composition benefit.

A 2026 scientific review highlights an important evidence gap: controlled human research on CJC-1295 without DAC is lacking. Findings from the DAC-modified compound or related peptides should not automatically be applied to the No-DAC formulation.

Understanding Ipamorelin

Ipamorelin is a peptide investigated for its activity at the ghrelin receptor (GHS-R1a), a pathway involved in growth hormone secretion. Its mechanism differs from GHRH-related signaling, which is why the two compounds are often discussed separately in scientific literature.

Research into receptor activity and hormone signaling does not, by itself, prove that Ipamorelin improves sleep, increases muscle mass, reduces body fat, accelerates recovery, or slows aging. Such outcomes require suitable clinical evidence for the specific compound and intended use.

How the Two Research Pathways Differ

CJC-1295 No DAC is associated with GHRH-related signaling, while Ipamorelin is associated with ghrelin-receptor signaling. These are distinct pathways involved in the body’s regulation of growth hormone.

That distinction provides useful scientific context, but it does not demonstrate that combining the peptides produces superior results. The safety, efficacy, optimal use, and long-term effects of this exact 5 mg + 5 mg formulation have not been established by the product label or the existence of research on the individual ingredients.

Product Composition and Documentation

The listed formulation contains:

• CJC-1295 No DAC: 5 mg
• Ipamorelin: 5 mg
• Total labeled peptide content: 10 mg per vial

The listed amounts describe the stated formulation, not independently verified laboratory findings.

For accurate product identification, consult the product label and any available batch-specific documentation. Where a certificate of analysis (COA) is provided, review the batch or lot number, identity testing, analytical methods, purity results, and other applicable quality measures. Claims about testing, purity, or manufacturing quality should only be made when supported by relevant documentation.

A COA does not establish clinical efficacy, human safety, or regulatory approval.

Safety and Regulatory Considerations

CJC-1295 and Ipamorelin have important evidence limitations. The U.S. Food and Drug Administration has identified potential concerns associated with certain compounded products containing CJC-1295 and Ipamorelin acetate, including possible immunogenicity and peptide-related impurities. FDA materials also describe limited clinical safety information for CJC-1295 and insufficient information to determine the safety of Ipamorelin acetate for certain routes of administration.

These concerns should not be interpreted as proof that every product has the same quality or risk profile. They do mean that the safety of a particular formulation should not be assumed without appropriate evidence.

This product description does not establish that the formulation is approved for medical treatment or proven for hormone optimization, anti-aging, muscle growth, fat loss, sleep improvement, or recovery. It is provided for educational and research-reference purposes only, not as medical advice or instructions for human use. Regulatory requirements vary by jurisdiction, so applicable rules should be checked before purchasing, handling, or distributing peptide products.

Frequently Asked Questions

What is CJC-1295 No DAC 5mg + Ipamorelin 5mg?

It is a two-peptide formulation whose listed ingredients are 5 mg of CJC-1295 No DAC and 5 mg of Ipamorelin, totaling 10 mg of labeled peptide content per vial.

What does “No DAC” mean?

DAC stands for Drug Affinity Complex, a modification associated with a longer duration of action in DAC-containing CJC-1295 formulations. The term “No DAC” indicates that this modification is not intended to be present, but the precise identity of a product should be confirmed through reliable documentation.

How are CJC-1295 No DAC and Ipamorelin different?

They are associated with different signaling pathways: CJC-1295 No DAC with GHRH-related signaling, and Ipamorelin with the ghrelin receptor. Different mechanisms do not prove that combining the peptides produces a specific clinical benefit.

Does this combination have proven anti-aging or muscle-building benefits?

The exact combination has not been established as a proven treatment for anti-aging, muscle growth, fat loss, or other health outcomes. Mechanistic explanations and findings from related compounds should not be presented as proof of clinical effectiveness.

Where can I find product-quality information?

Consult the product label and request applicable batch-specific documentation from the supplier. Any testing or purity statements should accurately reflect the documentation available for that specific product.

Additional Information

For further context, consult credible scientific and regulatory sources on CJC-1295, Ipamorelin, peptide characterization, and the limitations of current clinical evidence. Peptika product information should prioritize accurate composition details, transparent documentation, and responsible scientific communication.